Medicinal Cannabis and the Tyranny of Distance: Policy Reform Required for Optimizing Patient and Health System Net Benefit in Australia

This is a preview of subscription content, access via your institution.


  1. 1.

    Rogers E. Diffusion of innovations. New York: Free Press of Glencoe; 1962.

    Google Scholar 

  2. 2.

    Medical Marijuana Market Analysis By Application, (Chronic Pain, Arthritis, Migraine, Cancer) By Country (US, Canada, France, Italy, Switzerland, Israel, Belgium, Croatia, Finland, Netherlands, Portugal, Czech Republic, Estonia), and segment forecasts, 2013–2025. 2017.

  3. 3.

    de Bruin D, Ahmad T, Avendano JE, Sajanlal M, Edelstein A, Ryskin M. Medical cannabis has high potential: a joint biotech & tools primer. New York: Bank of America Merril Lynch; 2015.

    Google Scholar 

  4. 4.

    The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. The National Academies Press, ed. E. Committee on the Health Effects of Marijuana: an evidence review and research agenda; Board on Population and Public Health Practice; Health and Medicine Division; National Academies of Sciences. 2017: The National Academies Press.

  5. 5.

  6. 6.

    Harris G. Researchers find study of medical marijuana discourarged. 2010.

  7. 7.

    Mather L, Rauwendaal ER, Moxham-Hall VL, Wodak A. (Re)introducing medicinal cannabis. Med J Aust. 2013;199(11):759–61.

    Article  PubMed  Google Scholar 

  8. 8.

    Eckermann S. Health economics from theory to practice: optimally informing joint decisions of research, reimbursement and regulation with health system budget constraints and community objectives. Switzerland: Springer; 2017.

    Book  Google Scholar 

  9. 9.

    Bachhuber MA, et al. Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999–2010. JAMA Intern Med. 2014;174(10):1668–73.

    Article  PubMed  PubMed Central  Google Scholar 

  10. 10.

    Bradford AC, Bradford WD. Medical marijuana laws reduce prescription medication use in medicare part D. Health Aff (Millwood). 2016;35(7):1230–6.

    Article  Google Scholar 

  11. 11.

    Gallily R, Yekhtin Z, Hanus LO. Overcoming the bell-shaped dose-response of cannabidiol by using cannabis extract enriched in cannabidiol. Pharmacol Pharm. 2015;6(2):75–85.

    CAS  Article  Google Scholar 

  12. 12.

    Johnson JR, et al. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage. 2010;39(2):167–79.

    Article  PubMed  Google Scholar 

  13. 13.

    Carter GT, Weydt P, Kyashna-Tocha M, Abrams DI. Medicinal cannabis: rational guidelines for dosing. IDrugs. 2004;7(5):464–70.

    CAS  PubMed  Google Scholar 

  14. 14.

    Medical Cannabis Reform in Israel. 2017.

  15. 15.

    Caulkins JP, 2010. Estimated cost of production for legalized cannabis. Rand Corporation Working Paper 764, July 2010. Available online 21st July 2016:

  16. 16.

    Pekarsky B. The new drug reimbursement game: a regulator’s guide to playing and winning. London: Springer; 2015.

    Book  Google Scholar 

  17. 17.

    Eckermann S, Pekarsky B. Can the real opportunity cost stand up: displaced services, the straw man outside the room. PharmacoEconomics. 2014;32(4):319–25.

    Article  PubMed  Google Scholar 

  18. 18.

    McCaffrey N, Eckermann S. Raise the bar, not the threshold value: meeting patient preferences for palliative and end-of-life care. PharmacoEconomics Open. 2017.

    Google Scholar 

  19. 19.

    Carter G, et al. Cannabis in palliative medicine: improving care and reducing opioid-related morbidity. Am J Hosp Palliat Care. 2011;28:297–303.

    Article  PubMed  Google Scholar 

  20. 20.

  21. 21.

    Regulator of Medical Cannabis bill, 2014.

  22. 22.

    Medicinal cannabis: Government accused of defying will of Senate over importation

  23. 23.

    Nelson S. Fentanyl maker donates big to campaign opposing pot legalisation. 2016.

  24. 24.

    Fang L. Leading anti-marijuana academics are paid by painkiller drug companies. 2014.

Download references

Author information



Corresponding author

Correspondence to David Caldicott.

Ethics declarations

This commentary received no financial funding.

David Caldicott, Justin Sinclair, Lynnaire Sheridan and Simon Eckermann have no conflicts of interest. David Caldicott is a member of the ACT Medical Cannabis Advisory Group. Justin Sinclair, David Caldicott and Simon Eckermann are members on the Scientific Board of United in Compassion. Justin Sinclair is a member of the Scientific Advisory Board of BioCeuticals.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Caldicott, D., Sinclair, J., Sheridan, L. et al. Medicinal Cannabis and the Tyranny of Distance: Policy Reform Required for Optimizing Patient and Health System Net Benefit in Australia. Appl Health Econ Health Policy 16, 153–156 (2018).

Download citation